亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome

医学 美罗华 他克莫司 肾病综合征 皮质类固醇 内科学 儿科 免疫学 移植 抗体
作者
Biswanath Basu,Anja Sander,Birendranath Roy,Stella Preussler,Shilpita Barua,T. K. S. Mahapatra,Franz S. Schaefer
出处
期刊:Archives of pediatrics & adolescent medicine [American Medical Association]
卷期号:172 (8): 757-757 被引量:153
标识
DOI:10.1001/jamapediatrics.2018.1323
摘要

Importance: Calcineurin inhibitors are an established first-line corticosteroid-sparing therapy for patients with corticosteroid-dependent nephrotic syndrome (CDNS), whereas B-lymphocyte-depleting therapy is mostly used as a rescue for calcineurin inhibitor-resistant cases. The positive efficacy and safety profile of rituximab raises the question of whether it could be used as a first-line alternative to calcineurin inhibitor therapy. Objective: To compare the efficacy of rituximab and tacrolimus in maintaining relapse-free survival among children with CDNS. Design, Setting, and Participants: A parallel-arm, open-label, randomized clinical trial was performed from May 8, 2015, to September 20, 2016, with 1-year follow-up in a single-center, tertiary care unit. A total of 176 consecutive children aged 3 to 16 years with CDNS not previously treated with corticosteroid-sparing agents were screened for eligibility. Interventions: The children received either tacrolimus (along with tapering alternate-day prednisolone) for 12 months or a single course of rituximab (2 infusions of 375 mg/m2). Main Outcomes and Measures: Twelve-month relapse-free survival in the intention-to-treat population. Results: Of the 176 children screened for eligibility, 120 were randomized and all but 3 patients completed 1 year of follow-up. The groups were comparable, with mean (SD) age of 7.2 (2.8) years, 32 boys (53.3%) in each group, mean (SD) disease duration of 2.5 (1.5) years and 2.3 (1.7) in the tacrolimus and rituximab groups, respectively, disease duration less than 1 year among 15 children (25.0%) in each group, median (interquartile range) of 4 (3-5) relapses in each group, and mean (SD) cumulative prednisolone dose of 246 (48) mg/kg and 239 (52) mg/kg in the prestudy year in the tacrolimus and rituximab groups, respectively. Rituximab therapy was associated with a higher 12-month relapse-free survival rate than tacrolimus (54 [90.0%] vs 38 [63.3%] children; P < .001; odds ratio, 5.21; 95% CI, 1.93-14.07). Among the patients who experienced relapse, median time to first relapse was 40 weeks in the rituximab group and 29 weeks in the tacrolimus group. Only 2 patients in the rituximab group had more than 1 relapse during the study period compared with 10 patients in the tacrolimus group. The cumulative corticosteroid dose during the 12-month study period was lower with rituximab compared with tacrolimus (mean [SD], 25.8 [27.8] vs 86.3 [58.0] mg/kg). Although both treatments were well tolerated, mild to moderate infections were twice as common in the tacrolimus group (26 [43.3%] vs 13 [21.7%] events). Conclusions and Relevance: In children with CDNS, rituximab appears to be more effective than tacrolimus in maintaining disease remission and minimizing corticosteroid exposure and, given its good tolerability and lack of nephrotoxic effects, may be considered as first-line corticosteroid-sparing therapy. Trial Registration: ClinicalTrials.gov Identifier: NCT02438982; Clinical Trial Registry of India: CTRI/2014/01/004355.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
优美的烙完成签到,获得积分10
1秒前
研猫发布了新的文献求助10
1秒前
3秒前
6秒前
8952331完成签到 ,获得积分10
6秒前
宁静致远完成签到 ,获得积分10
6秒前
梦寐发布了新的文献求助10
7秒前
pzh完成签到 ,获得积分10
7秒前
AsahiKokura214完成签到,获得积分10
8秒前
8秒前
9秒前
9秒前
标致茈完成签到,获得积分10
10秒前
11秒前
11秒前
朴实香露完成签到 ,获得积分10
13秒前
SciGPT的应助被感性的曼卉采纳,获得30
13秒前
WZT完成签到,获得积分20
13秒前
纯情的阁发布了新的文献求助10
14秒前
14秒前
纯情的阁发布了新的文献求助10
15秒前
纯情的阁发布了新的文献求助10
15秒前
15秒前
烟花的应助被磊4165564采纳,获得10
15秒前
纯情的阁发布了新的文献求助10
15秒前
16秒前
Ava的应助被lysteph采纳,获得10
16秒前
17秒前
17秒前
纯情的阁发布了新的文献求助10
17秒前
18秒前
李志侠完成签到 ,获得积分10
18秒前
研猫发布了新的文献求助10
18秒前
纯情的阁发布了新的文献求助50
18秒前
纯情的阁发布了新的文献求助10
18秒前
纯情的阁发布了新的文献求助10
18秒前
卿卿发布了新的文献求助10
19秒前
纯情的阁发布了新的文献求助10
19秒前
Sweety_完成签到 ,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554315
关于积分的说明 21718840
捐赠科研通 7747967
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551811
邀请新用户注册赠送积分活动 2471239